Literature DB >> 32535976

Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study.

F Benhadou1, P D Ghislain2, F Guiot3, F Willaert1, V Del Marmol1, J Lambert4, R Soenen4, H Fierens5, M de la Brassinne6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32535976     DOI： 10.1111/jdv.16715

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  3 in total

1.  Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice.

Authors:  Yi-Teng Hung; Yu-Jr Lin; Hsien-Yi Chiu; Yu-Huei Huang
Journal:  Ther Adv Chronic Dis       Date:  2021-09-29       Impact factor: 5.091

Review 2.  Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.

Authors:  Angelo Ruggiero; Vincenzo Picone; Fabrizio Martora; Gabriella Fabbrocini; Matteo Megna
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-16

3.  Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.

Authors:  Angelo Ruggiero; Gabriella Fabbrocini; Eleonora Cinelli; Matteo Megna
Journal:  Dermatol Ther       Date:  2021-11-30       Impact factor: 3.858
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.